NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:
Allergan plc AGN
The investigation concerns whether Allergan and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Allergan to AbbVie Inc. Under the terms of the proposed transaction, Allergan shareholders would receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share. If you are an Allergan shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/allergan-plc-agn-stock-merger-abbvie/.
Oritani Financial Corp. ORIT
The investigation concerns whether Oritani and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Oritani to Valley National Bancorp for 1.60 shares of Valley common stock for each share of Oritani common stock. If you are an Oritani shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/oritani-financial-corp-orit-stock-merger-valley-national-bancorp/.
Milacron Holdings Corp. MCRN
The investigation concerns whether Milacron and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Milacron to Hillenbrand, Inc. for $11.80 in cash and 0.1612 shares of Hillenbrand common stock for each share of Milacron common stock. If you are a Milacron shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/milacron-holdings-corp-mcrn-merger-stock-hillenbrand/.
Genomic Health, Inc. GHDX
The investigation concerns whether Genomic Health and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Genomic Health to Exact Sciences Corp. Under the terms of the deal, Genomic Health stockholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock (subject to a 10% collar centered on Exact Sciences' volume-weighted average price for the 45 trading days ended July 26, 2019) for each share of Genomic Health common stock they own. If you are a Genomic Health shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/genomic-health-inc-ghdx-merger-stock-exact-sciences/.
On behalf of shareholders of these companies, Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
